X4 Pharmaceuticals Secures $150 Million Debt Facility

Key Facts

1X4 Pharmaceuticals entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures.

2The company used part of the new funding to complete the repayment of its existing loan facility.

3The company expects to complete enrollment in its Phase 3 4WARD trial by the end of 2026.

X4 Pharmaceuticals entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures. GlobeNewswire reported that the company used a portion of the new funding to complete the repayment of its existing loan facility. The financing is intended to provide capital for the company's corporate and commercial activities.

XFOR closed at $2.81 on October 7, 2026, prior to the announcement of the new debt facility. The company expects to complete enrollment in its Phase 3 4WARD trial by the end of 2026, supporting its ongoing clinical development in the rare hematology space.